• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Sana Biotechnology Inc. (Amendment)

    3/7/24 7:01:22 AM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SANA alert in real time by email
    SC 13G/A 1 sanabiotechnology29022024.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Sana Biotechnology, Inc. (Amendment No.3) ----------------------------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------------------------- (Title of Class of Securities) 799566104 ----------------------------------------------------------------------- (CUSIP Number) 29 February 2024 ----------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1745 (3-06) CUSIP No. 799566104 _______________________________________________________________________ 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Baillie Gifford & Co (Scottish partnership) _______________________________________________________________________ 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a).................................................................... (b).................................................................... _______________________________________________________________________ 3. SEC Use Only _______________________________________________________________________ 4. Citizenship or Place of Organization SCOTLAND UK _______________________________________________________________________ Number of 5. Sole Voting Power 10,345,664 Shares Bene ______________________________________________________ ficially by 6. Shared Voting Power 0 Owned by Each ______________________________________________________ Reporting 7. Sole Dispositive Power 10,360,620 Person With: ______________________________________________________ 8. Shared Dispositive Power 0 _______________________________________________________________________ 9. Aggregate Amount Beneficially Owned by Each Reporting Person 10,360,620 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 11. Percent of Class Represented by Amount in Row (9) 4.70% _______________________________________________________________________ 12. Type of Reporting Person (See Instructions) IA _______________________________________________________________________ Item 1. (a) Name of Issuer Sana Biotechnology, Inc. (b) Address of Issuers Principal Executive Offices 188 East Blaine Street Suite 400 Seattle, WA 98102 Item 2. (a) Name of Person Filing Baillie Gifford & Co (b) Address of Principal Business Office or, if none, Residence Calton Square 1 Greenside Row Edinburgh EH1 3AN Scotland UK (c) Citizenship Scotland UK (d) Title of Class of Securities Common Stock (e) CUSIP Number 799566104 Item 3. If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). (e) An investment adviser in accordance with rule 240.13d- 1(b)(1)(ii)(E) (f) An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F) (g) A parent holding company or control person in accordance with rule 240.13d-1(b) (1)(ii)(G) (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813) (j) X A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); (k) Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____ Item 4. Ownership. Provide the following information regarding the aggregate number and Percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: see row (9) on page 2. (b) Percent of Class: see row (11) on page 2. (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote See row (5) on page 2. (ii) Shared power to vote or to direct the vote See row (6) on page 2 (iii) Sole power to dispose or to direct the disposition of See row (7) on page 2 (iv) Shared power to dispose or to direct the disposition of See row (8) on page 2 Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. [x] Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not applicable. Item 8. Identification and Classification of Members of the Group Not applicable. Item 9. Notice of Dissolution of Group Not applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief: - the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. - the foreign regulatory scheme applicable to investment advisers is substantially comparable to the functionally equivalent U.S. institution(s). I also undertake to furnish the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D. SIGNATURE After reasonable enquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct 07 March 2024 ________________________________ Date Grant Meikle _______________________________________ Signature Grant Meikle Compliance Manager _______________________________________ Name/Title The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representatives authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule,including all exhibits. See rule 240.13d- 7 for other parties for whom copies are to be sent. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
    Get the next $SANA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SANA

    DatePrice TargetRatingAnalyst
    7/3/2025$12.00Overweight
    Morgan Stanley
    3/18/2025$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    3/14/2025$7.00Buy
    Jefferies
    1/8/2025Hold → Buy
    TD Cowen
    11/5/2024Mkt Outperform → Mkt Perform
    JMP Securities
    6/26/2024$16.00Buy
    Rodman & Renshaw
    1/16/2024$12.00Neutral → Buy
    H.C. Wainwright
    9/25/2023$9.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $SANA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Nelsen Robert bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      2/12/24 5:46:20 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Crandell Keith bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      2/12/24 5:43:56 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arch Venture Fund X, L.P. bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      2/12/24 5:43:09 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley resumed coverage on Sana Biotechnology with a new price target

      Morgan Stanley resumed coverage of Sana Biotechnology with a rating of Overweight and set a new price target of $12.00

      7/3/25 7:51:55 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sana Biotechnology upgraded by Citizens JMP with a new price target

      Citizens JMP upgraded Sana Biotechnology from Mkt Perform to Mkt Outperform and set a new price target of $5.00

      3/18/25 7:56:06 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on Sana Biotechnology with a new price target

      Jefferies initiated coverage of Sana Biotechnology with a rating of Buy and set a new price target of $7.00

      3/14/25 7:41:20 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    Leadership Updates

    Live Leadership Updates

    See more
    • Ted Myles Joins Cellarity as Chief Executive Officer

      Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating

      5/12/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics

      CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec

      4/29/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

      Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome autoimmune and allogeneic immune recognition, function, and persist with stable C-peptide production post-transplant Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect to report clinical data from both studies in 2025 Presented preclinical data in non-human primates showing safety and deep B cell depletion using a surrogate for SG299, an in viv

      3/17/25 4:05:00 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    Financials

    Live finance-specific insights

    See more
    • Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

      First-in-Human Study Provides Evidence that Sana's Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes Function and Persistence of Pancreatic Islets Were Detectable by Production of Consistent Levels of Circulating C-Peptide, a Marker of Insulin Production, and Increased C-Peptide Levels with a Mixed Meal Tolerance Test (MMTT) MRI Shows Signals Consistent with Graft Survival 28 Days after Transplantation Study Contin

      1/7/25 4:05:00 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    SEC Filings

    See more
    • Sana Biotechnology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Sana Biotechnology, Inc. (0001770121) (Filer)

      6/23/25 10:10:46 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sana Biotechnology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Sana Biotechnology, Inc. (0001770121) (Filer)

      6/6/25 4:05:17 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Sana Biotechnology Inc.

      424B5 - Sana Biotechnology, Inc. (0001770121) (Filer)

      5/8/25 4:44:44 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Flagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology Platform

      Solutions focus on enhancing crop resilience, protecting yields, and addressing critical challenges in the global food system The company emerges after four years of platform development with an initial commitment of $50 million from Flagship Pioneering CAMBRIDGE, Mass., July 1, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Terrana Biosciences™, a company pioneering RNA-based agricultural solutions to deliver protective and enhanced crop traits without altering the plant genome. Through its proprietary RNA technology platform, Terrana is developing targeted products designed to work at any time in a plant's lifecycle, enabling a continuous prod

      7/1/25 6:30:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

      SEATTLE, June 09, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced an upcoming podium presentation highlighting ongoing clinical data from the investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. The presentation will be held during a joint American Diabetes Association (ADA)/International Pancreas & Islet Transplant Association (IPITA) symposium at the 85th Annual ADA Scientific Sessions taking p

      6/9/25 4:05:00 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sana Biotechnology to Present at June 2025 Investor Conferences

      SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update. Sana will present at the Jefferies Global Healthcare Conference at 2:35 p.m. ET on Wednesday, June 4, 2025.Sana will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 8:40 a.m. ET on Tuesday, June 10, 2025. The webcasts will be accessible on the Investor Relations page of Sana's website at https://sana.com/. A replay of each presentation will be availa

      5/28/25 4:05:00 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bishop Hans Edgar was granted 7,842 shares, increasing direct ownership by 0.13% to 5,828,955 units (SEC Form 4)

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      7/8/25 4:17:31 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Rosiello Robert L.

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      6/9/25 4:40:33 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Bilenker Joshua H.

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      6/9/25 4:40:28 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

      SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

      11/14/24 5:12:32 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

      SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

      11/14/24 6:00:14 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

      SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

      11/12/24 4:52:24 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care